Our Subsidiaries
Our subsidiaries complement and enhance our core business, and they are integral to our vision to be a leader of the development of tomorrow's life science solutions and serve the global life science market with tools for drug development and companion diagnostics solutions.
Wieslab AB
Wieslab, a part of Svar Life Science in Malmö, Sweden, specializes in delivering diagnostic laboratory services. Our focus areas encompass neuro-immunology, nephrology, rheumatology, and gastroenterology, offering an extensive range of esoteric clinical diagnostic tests for clinicians and laboratories worldwide.
Wieslab Diagnostic Services is committed to providing high-quality, fast laboratory services to meet your specific needs, offering one of the most comprehensive autoimmune testing services. We continuously update our test portfolio by evaluating, developing, and validating new testing services, ensuring we remain at the forefront of autoimmunity testing.
Quality is at the core of our operations. We were among the first private laboratories accredited by SWEDAC and now adhere to ISO 15189, meeting the high standards of Sweden and the EU. Our laboratory services also align with the Swedac Good Laboratory Practice (GLP) program, ensuring compliance with regulatory requirements.
Our ultimate aim is to provide laboratory and clinical physicians with a reliable decision-making basis for patient treatment, offering fast and precise results.
Calpro AS
Calpro AS, a Norwegian biotech company and part of the Svar Life Science family, is a leading force in the research and development of Calprotectin-based diagnostic tests. We specialize in harnessing the potential of this unique biomarker to transform diagnostics.
Calprotectin is a key protein, constituting about 60% of the cytosol of Neutrophils. It is released during immune system activation in response to infections and is pivotal in diagnosing inflammatory bowel disease (IBD), differentiating it from irritable bowel syndrome (IBS). Calprotectin also plays a crucial role in tracking IBD patient progress, predicting relapses, and assessing treatment responses. Its stability, robustness, and localized release without synthesis make it a preferred biomarker for IBD and various other diseases.
We are committed to revolutionizing IBD patient care with E-Health, an emerging technology that allows patients to stay in remission for extended periods. Unlike phone or online consultations, E-Health provides objective data to healthcare providers. When implemented correctly, it offers immense benefits to patients, physicians, hospitals, and society. E-Health can significantly reduce the use of heavy medications, emergency admissions, surgeries, and costly treatments.
